The Human Jejunum Has an Endogenous Microbiota That Differs from Those in the Oral Cavity and Colon Olof H
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Using High Throughput Sequencing to Explore the Biodiversity in Oral Bacterial Communities Patricia I
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by OpenCommons at University of Connecticut University of Connecticut OpenCommons@UConn UCHC Articles - Research University of Connecticut Health Center Research 6-2012 Using High Throughput Sequencing to Explore the Biodiversity in Oral Bacterial Communities Patricia I. Diaz University of Connecticut School of Medicine and Dentistry A. K. Dupuy University of Connecticut - Storrs L. Abusleme University of Connecticut School of Medicine and Dentistry B. Reese University of Connecticut - Storrs C. Obergfell University of Connecticut - Storrs See next page for additional authors Follow this and additional works at: https://opencommons.uconn.edu/uchcres_articles Part of the Life Sciences Commons Recommended Citation Diaz, Patricia I.; Dupuy, A. K.; Abusleme, L.; Reese, B.; Obergfell, C.; Choquette, Linda E.; Dongari-Bagtzoglou, Anna; Peterson, Douglas E.; and Strausbaugh, Linda D., "Using High Throughput Sequencing to Explore the Biodiversity in Oral Bacterial Communities" (2012). UCHC Articles - Research. 209. https://opencommons.uconn.edu/uchcres_articles/209 Authors Patricia I. Diaz, A. K. Dupuy, L. Abusleme, B. Reese, C. Obergfell, Linda E. Choquette, Anna Dongari- Bagtzoglou, Douglas E. Peterson, and Linda D. Strausbaugh This article is available at OpenCommons@UConn: https://opencommons.uconn.edu/uchcres_articles/209 NIH Public Access Author Manuscript Mol Oral Microbiol. Author manuscript; available in PMC 2013 October 03. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Mol Oral Microbiol. 2012 June ; 27(3): 182–201. doi:10.1111/j.2041-1014.2012.00642.x. Using high throughput sequencing to explore the biodiversity in oral bacterial communities P.I. -
Human Milk Microbiota in Sub-Acute Lactational Mastitis Induces
www.nature.com/scientificreports OPEN Human milk microbiota in sub‑acute lactational mastitis induces infammation and undergoes changes in composition, diversity and load Alba Boix‑Amorós1,2,4, Maria Teresa Hernández‑Aguilar3, Alejandro Artacho2, Maria Carmen Collado1,5 & Alex Mira1,5* Sub‑acute mastitis (SAM) is a prevalent disease among lactating women, being one of the main reasons for early weaning. Although the etiology and diagnosis of acute mastitis (AM) is well established, little is known about the underlying mechanisms causing SAM. We collected human milk samples from healthy and SAM‑sufering mothers, during the course of mastitis and after symptoms disappeared. Total (DNA‑based) and active (RNA‑based) microbiota were analysed by 16S rRNA gene sequencing and qPCR. Furthermore, mammary epithelial cell lines were exposed to milk pellets, and levels of the pro‑infammatory interleukin IL8 were measured. Bacterial load was signifcantly higher in the mastitis samples and decreased after clinical symptoms disappeared. Bacterial diversity was lower in SAM milk samples, and diferences in bacterial composition and activity were also found. Contrary to AM, the same bacterial species were found in samples from healthy and SAM mothers, although at diferent proportions, indicating a dysbiotic ecological shift. Finally, mammary epithelial cell exposure to SAM milk pellets showed an over‑production of IL8. Our work therefore supports that SAM has a bacterial origin, with increased bacterial loads, reduced diversity and altered composition, which partly recovered after treatment, suggesting a polymicrobial and variable etiology. Human milk is a complex and live fuid, containing a relatively diverse and potential benefcial microbiota under healthy conditions1, which enhances gut microbiota colonization, likely stimulates commensal tolerance and supports the maturation of the immune system2–5. -
The Influence of Probiotics on the Firmicutes/Bacteroidetes Ratio In
microorganisms Review The Influence of Probiotics on the Firmicutes/Bacteroidetes Ratio in the Treatment of Obesity and Inflammatory Bowel disease Spase Stojanov 1,2, Aleš Berlec 1,2 and Borut Štrukelj 1,2,* 1 Faculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia; [email protected] (S.S.); [email protected] (A.B.) 2 Department of Biotechnology, Jožef Stefan Institute, SI-1000 Ljubljana, Slovenia * Correspondence: borut.strukelj@ffa.uni-lj.si Received: 16 September 2020; Accepted: 31 October 2020; Published: 1 November 2020 Abstract: The two most important bacterial phyla in the gastrointestinal tract, Firmicutes and Bacteroidetes, have gained much attention in recent years. The Firmicutes/Bacteroidetes (F/B) ratio is widely accepted to have an important influence in maintaining normal intestinal homeostasis. Increased or decreased F/B ratio is regarded as dysbiosis, whereby the former is usually observed with obesity, and the latter with inflammatory bowel disease (IBD). Probiotics as live microorganisms can confer health benefits to the host when administered in adequate amounts. There is considerable evidence of their nutritional and immunosuppressive properties including reports that elucidate the association of probiotics with the F/B ratio, obesity, and IBD. Orally administered probiotics can contribute to the restoration of dysbiotic microbiota and to the prevention of obesity or IBD. However, as the effects of different probiotics on the F/B ratio differ, selecting the appropriate species or mixture is crucial. The most commonly tested probiotics for modifying the F/B ratio and treating obesity and IBD are from the genus Lactobacillus. In this paper, we review the effects of probiotics on the F/B ratio that lead to weight loss or immunosuppression. -
The Efficacy and Tolerability of Streptococcus Salivarius 24SMB
European Review for Medical and Pharmacological Sciences 2019; 23(1 Suppl.): 67-72 The efficacy and tolerability of Streptococcus salivarius 24SMB and Streptococcus oralis 89a administered as nasal spray in the treatment of recurrent upper respiratory tract infections in children D. PASSALI1, G.C. PASSALI2, E. VESPERINI3, S. COCCA3, I.C. VISCONTI4, M. RALLI4, L.M. BELLUSSI1 1Department of Medicine, Surgery and Neuroscience, ENT Clinic, University of Siena, Siena, Italy 2ENT Clinic, Catholic University of Sacred Heart, Rome, Italy 3Department of Ear, Nose and Throat, San Giovanni Hospital, Rome, Italy 4Department of Sense Organs, Sapienza University of Rome, Rome, Italy Abstract. – OBJECTIVE: Nasal administration Key Words of Streptococcus salivarius 24SMB and Strepto- Streptococcus salivarius 24SMB, Streptococcus ora- coccus oralis 89a has been proposed to reduce lis 89 a, Pharyngitis, Adenotonsillitis, Acute otitis media. the risk of new episodes of adenoiditis, tonsillitis and acute rhinosinusitis in children. PATIENTS AND METHODS: We enrolled 202 List of Abbreviations children with a recent diagnosis of recurrent upper URT: upper respiratory tract; TLR: Toll-like Receptors; respiratory tract infection. All the patients were COPD: Chronic Obstructive Pulmonary Disease; LPS: treated twice daily for 7 days each month for 3 lipopolysaccharide; AOM: acute otitis media. consecutive months with a nasal spray whose active agents were two specific bacterial strains: Streptococcus salivarius 24SMB and Streptococ- cus oralis 89a. Evaluation was performed at the end of treatment and at follow-up at 3, 6, and 12 months. Introduction RESULTS: Patients who completed the entire 90-day course of bacteriotherapy and the follow-up period showed a 64.3% reduction in their episodes The capability of microbes to adapt to their of upper respiratory tract infections compared to environment is evident in the human body as in the number of episodes recorded in the previous other living organisms. -
WO 2015/066625 Al 7 May 2015 (07.05.2015) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/066625 Al 7 May 2015 (07.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12Q 1/04 (2006.01) G01N 33/15 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US2014/06371 1 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 3 November 20 14 (03 .11.20 14) KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (25) Filing Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/898,938 1 November 2013 (01. 11.2013) (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: WASHINGTON UNIVERSITY [US/US] GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, One Brookings Drive, St. -
Burkholderia Cepacia Complex As Human Pathogens1
Journal of Nematology 35(2):212–217. 2003. © The Society of Nematologists 2003. Burkholderia cepacia Complex as Human Pathogens1 John J. LiPuma2 Abstract: Although sporadic human infection due to Burkholderia cepacia has been reported for many years, it has been only during the past few decades that species within the B. cepacia complex have emerged as significant opportunistic human pathogens. Individuals with cystic fibrosis, the most common inherited genetic disease in Caucasian populations, or chronic granulomatous disease, a primary immunodeficiency, are particularly at risk of life-threatening infection. Despite advances in our understanding of the taxonomy, microbiology, and epidemiology of B. cepacia complex, much remains unknown regarding specific human virulence factors. The broad-spectrum antimicrobial resistance demonstrated by most strains limits current therapy of infection. Recent research efforts are aimed at a better appreciation of the pathogenesis of human infection and the development of novel therapeutic and prophylactic strategies. Key words: Burkholderia cepacia, cystic fibrosis, human infection. Until relatively recently, Burkholderia cepacia had been B. cepacia, possess other factors that remain to be elu- considered a phytopathogenic or saprophytic bacterial cidated that also mediate pathogenicity in this condi- species with little potential for human infection. How- tion (Speert et al., 1994). Fortunately, CGD is a rela- ever, reports of sporadic human infection have ap- tively rare disease, having an average annual incidence peared in the biomedical literature, generally describ- of approximately 1/200,000 live births in the United ing infection in persons with some underlying disease States; this means there are approximately 20 persons or debilitation (Dailey and Benner, 1968; Poe et al., with CGD born each year in the United States. -
Developing a Genetic Manipulation System for the Antarctic Archaeon, Halorubrum Lacusprofundi: Investigating Acetamidase Gene Function
www.nature.com/scientificreports OPEN Developing a genetic manipulation system for the Antarctic archaeon, Halorubrum lacusprofundi: Received: 27 May 2016 Accepted: 16 September 2016 investigating acetamidase gene Published: 06 October 2016 function Y. Liao1, T. J. Williams1, J. C. Walsh2,3, M. Ji1, A. Poljak4, P. M. G. Curmi2, I. G. Duggin3 & R. Cavicchioli1 No systems have been reported for genetic manipulation of cold-adapted Archaea. Halorubrum lacusprofundi is an important member of Deep Lake, Antarctica (~10% of the population), and is amendable to laboratory cultivation. Here we report the development of a shuttle-vector and targeted gene-knockout system for this species. To investigate the function of acetamidase/formamidase genes, a class of genes not experimentally studied in Archaea, the acetamidase gene, amd3, was disrupted. The wild-type grew on acetamide as a sole source of carbon and nitrogen, but the mutant did not. Acetamidase/formamidase genes were found to form three distinct clades within a broad distribution of Archaea and Bacteria. Genes were present within lineages characterized by aerobic growth in low nutrient environments (e.g. haloarchaea, Starkeya) but absent from lineages containing anaerobes or facultative anaerobes (e.g. methanogens, Epsilonproteobacteria) or parasites of animals and plants (e.g. Chlamydiae). While acetamide is not a well characterized natural substrate, the build-up of plastic pollutants in the environment provides a potential source of introduced acetamide. In view of the extent and pattern of distribution of acetamidase/formamidase sequences within Archaea and Bacteria, we speculate that acetamide from plastics may promote the selection of amd/fmd genes in an increasing number of environmental microorganisms. -
(12) United States Patent (10) Patent No.: US 9,018,158 B2 Onsoyen Et Al
US0090181.58B2 (12) United States Patent (10) Patent No.: US 9,018,158 B2 Onsoyen et al. (45) Date of Patent: Apr. 28, 2015 (54) ALGINATE OLIGOMERS FOR USE IN 7,208,141 B2 * 4/2007 Montgomery .................. 424/45 OVERCOMING MULTIDRUG RESISTANCE 22:49 R: R388 al al W . aSOC ea. N BACTERA 7,671,102 B2 3/2010 Gaserod et al. 7,674,837 B2 3, 2010 G d et al. (75) Inventors: Edvar Onsoyen, Sandvika (NO); Rolf 7,758,856 B2 T/2010 it. Myrvold, Sandvika (NO); Arne Dessen, 7,776,839 B2 8/2010 Del Buono et al. Sandvika (NO); David Thomas, Cardiff 2006.8 R 38 8. Melist al. (GB); Timothy Rutland Walsh, Cardiff 2003/0022863 A1 1/2003 Stahlang et al. (GB) 2003/0224070 Al 12/2003 Sweazy et al. 2004/OO73964 A1 4/2004 Ellington et al. (73) Assignee: Algipharma AS, Sandvika (NO) 2004/0224922 A1 1 1/2004 King 2010.0068290 A1 3/2010 Ziegler et al. (*) Notice: Subject to any disclaimer, the term of this 2010/0305062 A1* 12/2010 Onsoyen et al. ................ 514/54 patent is extended or adjusted under 35 U.S.C. 154(b) by 184 days. FOREIGN PATENT DOCUMENTS DE 268865 A1 1, 1987 (21) Appl. No.: 13/376,164 EP O324720 A1 T, 1989 EP O 506,326 A2 9, 1992 (22) PCT Filed: Jun. 3, 2010 EP O590746 A1 4f1994 EP 1234584 A1 8, 2002 (86). PCT No.: PCT/GB2O1 O/OO1097 EP 1714660 A1 10, 2006 EP 1745705 A1 1, 2007 S371 (c)(1), FR T576 M 3/1968 (2), (4) Date: Jan. -
A Case Study of Salivary Microbiome in Smokers and Non-Smokers in Hungary: Analysis by Shotgun Metagenome Sequencing
Journal of Oral Microbiology ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/zjom20 A case study of salivary microbiome in smokers and non-smokers in Hungary: analysis by shotgun metagenome sequencing Roland Wirth , Gergely Maróti , Róbert Mihók , Donát Simon-Fiala , Márk Antal , Bernadett Pap , Anett Demcsák , Janos Minarovits & Kornél L. Kovács To cite this article: Roland Wirth , Gergely Maróti , Róbert Mihók , Donát Simon-Fiala , Márk Antal , Bernadett Pap , Anett Demcsák , Janos Minarovits & Kornél L. Kovács (2020) A case study of salivary microbiome in smokers and non-smokers in Hungary: analysis by shotgun metagenome sequencing, Journal of Oral Microbiology, 12:1, 1773067, DOI: 10.1080/20002297.2020.1773067 To link to this article: https://doi.org/10.1080/20002297.2020.1773067 © 2020 The Author(s). Published by Informa View supplementary material UK Limited, trading as Taylor & Francis Group. Published online: 07 Jun 2020. Submit your article to this journal Article views: 84 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=zjom20 JOURNAL OF ORAL MICROBIOLOGY 2020, VOL. 12, 1773067 https://doi.org/10.1080/20002297.2020.1773067 A case study of salivary microbiome in smokers and non-smokers in Hungary: analysis by shotgun metagenome sequencing Roland Wirtha, Gergely Marótib, Róbert Mihókc, Donát Simon-Fialac, Márk Antalc, Bernadett Papb, Anett Demcsákd, Janos Minarovitsd and Kornél L. Kovács -
Product Sheet Info
Product Information Sheet for HM-13 Oribacterium sinus, Strain F0268 2% yeast extract (ATCC medium 1834) or equivalent Wilkins-Chalgren anaerobe agar with 5% defibrinated sheep blood or equivalent Catalog No. HM-13 Incubation: Temperature: 37°C For research use only. Not for human use. Atmosphere: Anaerobic (80% N2:10% CO2:10% H2) Propagation: Contributor: 1. Keep vial frozen until ready for use, then thaw. Jacques Izard, Assistant Member of the Staff, Department of 2. Transfer the entire thawed aliquot into a single tube of Molecular Genetics, The Forsyth Institute, Boston, broth. Massachusetts 3. Use several drops of the suspension to inoculate an agar slant and/or plate. Manufacturer: 4. Incubate the tube, slant and/or plate at 37°C for 48 to BEI Resources 72 hours. Product Description: Citation: Bacteria Classification: Lachnospiraceae, Oribacterium Acknowledgment for publications should read “The following Species: Oribacterium sinus reagent was obtained through BEI Resources, NIAID, NIH as Strain: F0268 part of the Human Microbiome Project: Oribacterium sinus, Original Source: Oribacterium sinus (O. sinus), strain F0268 Strain F0268, HM-13.” was isolated in June 1980 from the subgingival plaque of a 27-year-old white female patient with severe periodontitis in Biosafety Level: 1 the United States.1,2 Appropriate safety procedures should always be used with Comments: O. sinus, strain F0268 (HMP ID 6123) is a this material. Laboratory safety is discussed in the following reference genome for The Human Microbiome Project publication: U.S. Department of Health and Human Services, (HMP). HMP is an initiative to identify and characterize Public Health Service, Centers for Disease Control and human microbial flora. -
WO 2018/064165 A2 (.Pdf)
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/064165 A2 05 April 2018 (05.04.2018) W !P O PCT (51) International Patent Classification: Published: A61K 35/74 (20 15.0 1) C12N 1/21 (2006 .01) — without international search report and to be republished (21) International Application Number: upon receipt of that report (Rule 48.2(g)) PCT/US2017/053717 — with sequence listing part of description (Rule 5.2(a)) (22) International Filing Date: 27 September 2017 (27.09.2017) (25) Filing Language: English (26) Publication Langi English (30) Priority Data: 62/400,372 27 September 2016 (27.09.2016) US 62/508,885 19 May 2017 (19.05.2017) US 62/557,566 12 September 2017 (12.09.2017) US (71) Applicant: BOARD OF REGENTS, THE UNIVERSI¬ TY OF TEXAS SYSTEM [US/US]; 210 West 7th St., Austin, TX 78701 (US). (72) Inventors: WARGO, Jennifer; 1814 Bissonnet St., Hous ton, TX 77005 (US). GOPALAKRISHNAN, Vanch- eswaran; 7900 Cambridge, Apt. 10-lb, Houston, TX 77054 (US). (74) Agent: BYRD, Marshall, P.; Parker Highlander PLLC, 1120 S. Capital Of Texas Highway, Bldg. One, Suite 200, Austin, TX 78746 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. -
Klebsiella Ornithinolytica
international Journal of Systematic Bacteriology (1 999), 49, 1695-1 700 Printed in Great Britain Phylogenetic evidence for reclassification of Calymmatobacterium granulomatis as Klebsiella granulomatis comb. nov. Jenny 5. Carter,’l2 Francis J. B~wden,~Ivan Ba~tian,~Garry M. Myers,’ K. S. Sriprakash’ and David J. Kemp’ Author for correspondence : David J. Kemp. Tel : + 6 18 8922 84 12. Fax : + 6 18 8927 5 187 e-mail : [email protected] 1 Menzies School of Health By sequencing a total of 2089 bp of the 16s rRNA and phoE genes it was Research, Darwin, demonstratedthat Calymmatobacterium grandomatis (the causative Austra Iia organism of donovanosis) shows a high level of identity with Klebsiella * Centre for Indigenous species pathogenic to humans (Klebsiellapneumoniae, Klebsiella Natural and Cultural Resource Management, rhinoscleromatis). It is proposed that C. grandomatis should be reclassified as Faculty of Aboriginal and Klebsiella granulomatis comb. nov. An emended description of the genus Torres Strait Islander Klebsiella is given. Studies, Northern Territory University, Darwin, Australia 3 Institute of Medical and Keywords : Calymmatobacteriurn, Klebsiella, sequence data, phylogenetic inferences Veterinary Science, Adelaide, Australia 4 AIDS/STD Unit, Royal Darwin Hospital, Darwin, Australia Calymmatobacterium granulomatis is the presumed ganism (Richens, 1991) have prevented further char- causative agent of donovanosis, an important cause of acterization of this relationship. genital ulceration that occurs in small endemic foci in all continents except Europe and Antarctica. The name Non-cultivable pathogenic eubacteria have been C. granulomatis was originally given to the pleo- identified by PCR using primers targeting conserved morphic bacterium cultured from donovanosis lesions genes (Fredricks & Relman, 1996).